NCT01080209

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 215 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

Conditions

• Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Interventions

Type	Name	Description
DRUG	Brimo PS DDS®	Patients who received Brimo PS DDS® intravitreal implant in a previous study.
OTHER	Sham	Patients who recieved sham in a previous study.

Timeline

• Start date: 2010-02-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2010-03-04
• Last updated: 2015-02-20
• Results posted: 2015-02-20

Locations

13 sites across 12 countries: United States, Australia, Czechia, France, Germany, India, Israel, Italy, Philippines, Portugal, South Korea, United Kingdom